Paul Parren | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Paul Parren is active.

Explore More

Publication

Featured researches published by Paul Parren.

Archive | 2004

Antibodies against insulin-like growth factor i receptor and uses thereof

Yvo Graus; Erhard Kopetzki; Klaus-Peter Kuenkele; Olaf Mundigl; Paul Parren; Frank Rebers; Ralf Schumacher; De Winkel Jan Van; Vugt Martine Van

Archive | 2005

Anti-OX40L Antibodies

Joseph Endl; Elsie M. Eugui; Maria E. Fuentes; Yvo Graus; Aran Frank Labrijn; Martin Lanzendoerfer; Paul Parren; Frank Rebers; Ralf Schumacher; Stefan Seeber; Jan van de Winkel; Martine van Vugt

Archive | 2005

Anti-P-selectin antibodies

Yvo Graus; Jacques Himber; Miranda Jansen-Molenaar; Dorothee Kling; Erhard Kopetzky; Paul Parren; Frank Rebers; Beat Steiner; Anne Stern; Pamela Strein; Kay-Gunnar Stubenrauch; De Winkel Jan Van; Vugt Martine Van

Archive | 2006

Antibodies against IL-13 receptor alpha1 and uses thereof

Josef Endl; Maria E. Fuentes; Yvo Graus; Adelbert Grossmann; Sebastian Neumann; Paul Parren; Frank Rebers; Joerg Thomas Regula; Ralf Schumacher; Stefan Seeber; Jan Olaf Stracke; Kay-Gunnar Stubenrauch; Jan van de Winkel; Martine van Vugt; Sandra Vereecken-Verploegen

Archive | 2012

Nucleic acid molecules encoding anti-P-selectin antibodies

Yvo Graus; Jacques Himber; Miranda Jansen-Molenaar; Dorothee Kling; Erhard Kopetzki; Paul Parren; Frank Rebers; Beat Steiner; Anne Stern; Pamela Braemer; Kay-Gunnar Stubenrauch; Jan van de Winkel; Martine van Vugt

Archive | 2010

Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies

Journal of Clinical Oncology | 2011

The potential of the human CD38-specific antibody daratumumab to improve the antimyeloma effect of novel multidrug therapies including patients refractory to lenalidomide or bortezomib.

Tuna Mutis; M. de Weers; M. S. van der Veer; Berris van Kessel; Joost M. Bakker; Shulamiet Wittebol; Paul Parren; H M Lokhorst

Journal of Clinical Oncology | 2010

Role of ADCC in the in vivo antitumor effects of zalutumumab, a human anti-EGF receptor antibody.

Marije B. Overdijk; Sandra Verploegen; J. Van den Brakel; J. J. Lammerts van Bueren; G. Rigter; Tom Vink; J. G. J. Van De Winkel; Paul Parren; Wim K. Bleeker

Archive | 2004

Antibody selection method against IGF-IR

Yvo Graus; Erhard Kopetzki; Klaus-Peter Kuenkele; Olaf Mundigl; Paul Parren; Frank Rebers; Ralf Schumacher; Jan van de Winkel; Martine Vriesema-van Vugt

Archive | 2006